Study drug SHR-A1811 with two lung cancer medicines
Part of Cancer, Lungs & breathing clinical trials.
This early-phase trial tests an injectable cancer drug (SHR-A1811) given with either pyrotinib or another targeted drug (SHR-1316) in people with advanced lung cancer. The goal is to see how safe the combination is and how well it can control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent and you can attend required study visits and tests
- You’re age 18 to 75, and you have advanced or metastatic non-small cell lung cancer
- Your cancer is considered “failed standard care” or you couldn’t tolerate standard treatments
- You have at least one measurable tumor spot and your vital organs (like liver/kidneys) work well
- Your heart function is acceptable and you have a good expected survival (at least 12 weeks)
- You can provide recent tumor tissue samples and you agree to use birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SHR-A1811 for people with advanced or metastatic non-small cell lung cancer that has a change (mutation) in the HER2 gene. You cannot have had any previous treatment for advanced lung cancer, and the cancer must be measurable outside the brain.
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
This Phase 1 study tests SHR-A2102, a new cancer medicine, in adults with advanced solid tumors. It mainly looks at safety and how the body handles the drug, and it may help if standard treatments are not working or are not an option.
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
This study tests two new drugs (SHR-A1921 and SHR-A2009) for people with advanced non-small cell lung cancer (NSCLC) whose cancer has progressed after previous treatments, including antibody-drug conjugate therapy. The goal is to see if these drugs can help control the cancer.
This trial tests a new drug, SHR-1826, for people with advanced or metastatic non-small cell lung cancer that has gotten worse after previous treatment. The goal is to see if the drug can help control the cancer.
Hear when a new Advanced Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.